Promoted Content
Promoted Content

Find Drugs for Infections and Infectious Diseases in Preclinical Development in CANADA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-1701

            Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Defense Threat Reduction Agency

            Deal Size: $6.3 million Upfront Cash: Undisclosed

            Deal Type: Funding October 27, 2020

            Details:

            Agreement with Ology Bioservices and a $6.3MM DTRA contract enable next stage of manufacturing and development for world’s first vaccine to prevent F. tularensis, a potential biological weapons threat.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apabetalone

            Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            Apabetalone was shown to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus to enter human cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LCTG-001

            Therapeutic Area: Infections and Infectious Diseases Product Name: LCTG-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Icahn School of Medicine

            Deal Size: $2.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership October 14, 2020

            Details:

            Lactiga entered a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. Partners secured an NIH R01 Emergency Award of over $2MM to advance this study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VBI-2901

            Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2901

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: VBI Vaccines

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 18, 2020

            Details:

            Under the terms of the agreement, Therapure will be responsible for the biomanufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at the Therapure facility in Mississauga, Ontario, Canada.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Yeast beta-glucans

            Therapeutic Area: Infections and Infectious Diseases Product Name: PGX-YBG

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 18, 2020

            Details:

            In-vitro study with human cell lines demonstrated that PGX-YBG obtained from different sources exhibited significant stimulatory effect on human immune response.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KG2019

            Therapeutic Area: Infections and Infectious Diseases Product Name: KG2019

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Government of Canada

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 14, 2020

            Details:

            The goal of this therapeutic platform is to both prevent SARS-Cov2 cellular invasion into these tissues (‘viral trap’) and to mitigate pathology triggered by the host response to the virus, including over-activation of immune system and lung and heart failure.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ivermectin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            Company has commenced two pre-clinical trials designed to demonstrate the efficacy of its proprietary Quicksome™ technology in overcoming key absorption limitations of the oral drug Ivermectin and report pharmacokinetic results of Quicksome™ oral strip sublingual technology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zileuton,Montelukast Sodium

            Therapeutic Area: Infections and Infectious Diseases Product Name: Zyflo

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            Novateur proposes a simple treatment paradigm using a combination of a leukotriene biosynthesis blocker, Zyflo® controlled release formulation and an inhibitor of the cysteinyl leukotriene 1 receptor, Singulair® to target the hyper-inflammatory response insevere COVID-19.

            IMV

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DPX-COVID-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: NRC IRAP

            Deal Size: $3.5 million Upfront Cash: Undisclosed

            Deal Type: Funding August 04, 2020

            Details:

            Fundng will support advancement of IMV's Phase 1 clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IgY-110

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: MMS Holdings

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 08, 2020

            Details:

            The partnership aims at further developing IgY-110, an anti-CoV-2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed.

            PharmaCompass